Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 332

1.

Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.

Venables ZC, Autier P, Nijsten T, Wong KF, Langan SM, Rous B, Broggio J, Harwood C, Henson K, Proby CM, Rashbass J, Leigh IM.

JAMA Dermatol. 2018 Nov 28. doi: 10.1001/jamadermatol.2018.4219. [Epub ahead of print]

PMID:
30484823
2.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Sherwood V, Thomson J, Hogan S, Spender LC, South AP, Stratton M, Chelala C, Harwood CA, Proby CM, Leigh IM.

Nat Commun. 2018 Sep 10;9(1):3667. doi: 10.1038/s41467-018-06027-1.

3.

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MC, der Meijden EV, Inman GJ, South AP, Leigh IM, Harwood CA.

Front Microbiol. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806. eCollection 2018.

4.

Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Hepburn LA, McHugh A, Fernandes K, Boag G, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 May 1;9(33):23029-23046. doi: 10.18632/oncotarget.25196. eCollection 2018 May 1.

5.

Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.

McHugh A, Fernandes K, South AP, Mellerio JE, Salas-Alanís JC, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 Apr 17;9(29):20265-20281. doi: 10.18632/oncotarget.24750. eCollection 2018 Apr 17.

6.

Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

Rose AM, Spender LC, Stephen C, Mitchell A, Rickaby W, Bray S, Evans AT, Dayal J, Purdie KJ, Harwood CA, Proby CM, Leigh IM, Coates PJ, Inman GJ.

Oncotarget. 2018 Feb 22;9(18):14552-14566. doi: 10.18632/oncotarget.24545. eCollection 2018 Mar 6.

7.

Genomic analysis of atypical fibroxanthoma.

Lai K, Harwood CA, Purdie KJ, Proby CM, Leigh IM, Ravi N, Mully TW, Brooks L, Sandoval PM, Rosenblum MD, Arron ST.

PLoS One. 2017 Nov 15;12(11):e0188272. doi: 10.1371/journal.pone.0188272. eCollection 2017.

8.

Keratinocyte skin cancers in the spotlight.

Nijsten T, Leigh IM.

Br J Dermatol. 2017 Aug;177(2):334-335. doi: 10.1111/bjd.15711. No abstract available.

PMID:
28833010
9.

Rhomboid family member 2 regulates cytoskeletal stress-associated Keratin 16.

Maruthappu T, Chikh A, Fell B, Delaney PJ, Brooke MA, Levet C, Moncada-Pazos A, Ishida-Yamamoto A, Blaydon D, Waseem A, Leigh IM, Freeman M, Kelsell DP.

Nat Commun. 2017 Jan 27;8:14174. doi: 10.1038/ncomms14174.

10.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

11.

WNT Signaling in Cutaneous Squamous Cell Carcinoma: A Future Treatment Strategy?

Sherwood V, Leigh IM.

J Invest Dermatol. 2016 Sep;136(9):1760-1767. doi: 10.1016/j.jid.2016.05.108. Epub 2016 Jul 19. Review.

12.

The European Union's Investment and Future Role in Dermatologic Research.

Leigh IM.

J Invest Dermatol. 2016 Jul;136(7):1307-1310. doi: 10.1016/j.jid.2016.04.034. No abstract available.

13.

MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.

Adelmann CH, Truong KA, Liang RJ, Bansal V, Gandee L, Saporito RC, Lee W, Du L, Nicholas C, Napoli M, Mino B, South AP, Proby CM, Leigh IM, Coarfa C, Flores ER, Tsai KY.

J Invest Dermatol. 2016 Sep;136(9):1920-1924. doi: 10.1016/j.jid.2016.05.110. Epub 2016 Jun 9. No abstract available.

14.

CREBBP mutation in human cutaneous squamous cell carcinoma.

Watt SA, Purdie KJ, den Breems NY, Dimon M, Tucker S, Arron ST, McHugh A, Xue DJ, Dayal JH, Harwood CA, Leigh IM, Proby CM, South AP.

Exp Dermatol. 2016 Aug;25(8):650-1. doi: 10.1111/exd.13044. Epub 2016 Jun 30. No abstract available.

PMID:
27094574
15.

Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa.

Watt SA, Dayal JH, Wright S, Riddle M, Pourreyron C, McMillan JR, Kimble RM, Prisco M, Gartner U, Warbrick E, McLean WH, Leigh IM, McGrath JA, Salas-Alanis JC, Tolar J, South AP.

PLoS One. 2015 Sep 18;10(9):e0137639. doi: 10.1371/journal.pone.0137639. eCollection 2015.

16.

Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.

Watt SA, Purdie KJ, den Breems NY, Dimon M, Arron ST, McHugh AT, Xue DJ, Dayal JH, Proby CM, Harwood CA, Leigh IM, South AP.

Am J Pathol. 2015 Sep;185(9):2354-63. doi: 10.1016/j.ajpath.2015.05.018. Epub 2015 Jul 26.

17.

The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.

Harwood CA, Proby CM, Inman GJ, Leigh IM.

Acta Derm Venereol. 2016 Jan;96(1):3-16. doi: 10.2340/00015555-2181. Review.

18.

Progress in skin cancer: the U.K. experience.

Leigh IM.

Br J Dermatol. 2014 Sep;171(3):443-5. doi: 10.1111/bjd.13258. No abstract available.

PMID:
25234058
19.

NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.

South AP, Purdie KJ, Watt SA, Haldenby S, den Breems N, Dimon M, Arron ST, Kluk MJ, Aster JC, McHugh A, Xue DJ, Dayal JH, Robinson KS, Rizvi SH, Proby CM, Harwood CA, Leigh IM.

J Invest Dermatol. 2014 Oct;134(10):2630-2638. doi: 10.1038/jid.2014.154. Epub 2014 Mar 24.

20.

High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.

Pourreyron C, Chen M, McGrath JA, Salas-Alanis JC, South AP, Leigh IM.

Br J Dermatol. 2014 Jun;170(6):1256-65. doi: 10.1111/bjd.12715.

PMID:
24641191

Supplemental Content

Loading ...
Support Center